Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / Brixton Biosciences

Approvalsnovel device granted (FDA De Novo)21 Aug 2026

Brixton Biosciences

21 Aug 2026: Novel device granted (FDA De Novo) · ReneuRx™ (Neural Ice). Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
21 Aug 2026
Device
ReneuRx™ (Neural Ice)
Specialty
Orthopedic
Product Code
SJA
Country
United States
Location
Cambridge, MA
Submitted
2025-12-15
Reference
DEN250067
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at Brixton Biosciences

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Brixton Biosciences in our registers.

More in Orthopedic

De Novo Grants

See all

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.